

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00858)

POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 30 AUGUST 2022

References are made to the circular (the “**Circular**”) and the notice (the “**Notice**”) of annual general meeting (the “**AGM**”) of Extrawell Pharmaceutical Holdings Limited (the “**Company**”) dated 29 July 2022. Unless the context otherwise requires, terms defined in this announcement shall have the same meanings as those defined in the Circular.

POLL RESULTS OF AGM

The board of directors (the “**Board**”) of the Company announces that all the proposed resolutions as set out in the Notice were duly passed by the shareholders of the Company (the “**Shareholders**”) by way of poll as ordinary resolutions at the AGM of the Company held on 30 August 2022.

As at the date of the AGM, the total number of issued shares of the Company was 2,390,000,000 shares, which was the total number of shares entitling the Shareholders to attend and vote for or against the resolutions proposed at the AGM. There were no shares entitling the Shareholders to attend and abstain from voting in favour pursuant to Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). There were no Shareholders that are required under the Listing Rules to abstain from voting.

Tricor Tengis Limited, the Company’s Hong Kong branch share registrar and transfer office, acted as the scrutineer for the vote-taking at the AGM.

The poll results are set out as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive and consider the audited financial statements and the reports of the directors and the auditor for the year ended 31 March 2022.	413,080,510 (100%)	0 (0%)
2.	(a) To re-elect Mr. Xue Jing Lun as independent non-executive director.	413,080,510 (100%)	0 (0%)
	(b) To re-elect Ms. Jin Song as independent non-executive director.	413,080,510 (100%)	0 (0%)
	(c) To authorise the board of directors of the Company to fix the directors' remuneration.	413,080,510 (100%)	0 (0%)
3.	To re-appoint the Company's auditor and authorise the board of directors to fix its remuneration.	413,080,510 (100%)	0 (0%)
4.	To grant a general mandate to the directors of the Company to allot, issue and otherwise deal with the Company's shares.	411,610,510 (99.64%)	1,470,000 (0.36%)
5.	To grant a general mandate to the directors of the Company to buy back the Company's shares.	413,080,510 (100%)	0 (0%)
6.	To extend the general mandate granted to the directors of the Company to allot, issue and deal with the Company's shares by the addition thereto the nominal amount of the shares bought back by the Company.	411,610,510 (99.64%)	1,470,000 (0.36%)
7.	To approve and adopt the new share option scheme.	411,610,510 (99.64%)	1,470,000 (0.36%)

As more than 50% of the votes were cast in favour of each of the above resolutions, all such resolutions were duly passed as ordinary resolutions.

The Company's directors, Ms. Wong Sau Kuen and Mr. Liu Kwok Wah attended the AGM in person, and Dr. Xie Yi, Mr. Cheng Yong, Dr. Lou Yi, Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song attended the AGM by electronic means.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 30 August 2022

As at the date of this announcement, the executive directors are Dr. Xie Yi, Mr. Cheng Yong, Dr. Lou Yi, Ms. Wong Sau Kuen and Mr. Liu Kwok Wah, and the independent non-executive directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.

* *For identification purpose only*